Raymond James Financial Services Advisors Inc. Invests $150,000 in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Raymond James Financial Services Advisors Inc. purchased a new position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 26,252 shares of the company’s stock, valued at approximately $150,000.

A number of other institutional investors and hedge funds have also made changes to their positions in CRBU. Bank of New York Mellon Corp grew its stake in shares of Caribou Biosciences by 29.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 264,243 shares of the company’s stock worth $1,263,000 after purchasing an additional 60,242 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Caribou Biosciences by 16.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 291,891 shares of the company’s stock worth $1,395,000 after buying an additional 40,222 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Caribou Biosciences by 32.8% in the 3rd quarter. Principal Financial Group Inc. now owns 25,198 shares of the company’s stock worth $120,000 after buying an additional 6,227 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Caribou Biosciences by 247.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,648,582 shares of the company’s stock worth $12,660,000 after buying an additional 1,886,484 shares in the last quarter. Finally, Jump Financial LLC purchased a new stake in shares of Caribou Biosciences in the 3rd quarter worth about $441,000. 77.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright boosted their price objective on shares of Caribou Biosciences from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th.

Caribou Biosciences Trading Down 2.3 %

NASDAQ:CRBU opened at $3.76 on Friday. The firm has a market cap of $339.60 million, a price-to-earnings ratio of -2.59 and a beta of 2.47. The company’s 50-day moving average is $5.59 and its two-hundred day moving average is $5.42. Caribou Biosciences, Inc. has a 12-month low of $3.44 and a 12-month high of $8.59.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Monday, March 11th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.17). The firm had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.17 million. Caribou Biosciences had a negative net margin of 296.05% and a negative return on equity of 31.06%. On average, equities research analysts forecast that Caribou Biosciences, Inc. will post -1.76 earnings per share for the current fiscal year.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.